Chronic Lymphocytic Lymphoma | Professor Dr Stephan Stilgenbauer

1:12:58
 
Share
 

Manage episode 242952772 series 2513286
By Dr Neil Love. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

Chronic Lymphocytic Lymphoma, Issue 2, 2019 — Part 1: Our interview with Prof Stilgenbauer highlights the following topics as well as cases from his practice:

  • Updated International Workshop on Chronic Lymphocytic Leukemia guidelines for diagnosis, indications for treatment, response assessment and management of chronic lymphocytic leukemia (CLL) (00:00)
  • Genetic abnormalities in CLL; effects of p53 mutations and 17p deletion on prognosis and therapy (02:48)
  • Design and eligibility for the Phase III CLL14 trial of venetoclax/obinutuzumab versus chlorambucil/obinutuzumab for patients with previously untreated CLL and coexisting medical conditions (05:42)
  • Recent data from the Phase III iLLUMINATE, Alliance A041202 and ECOG-E1912 trials comparing ibrutinib-based regimens to chemoimmunotherapy as first-line treatment for patients with CLL (07:51)
  • Results from the CLL14 trial comparing venetoclax to chlorambucil as an addition to fixed-duration obinutuzumab therapy for CLL (10:17)
  • Management of disease relapse on the CLL14 trial; role of minimal residual disease (MRD) assessment in therapeutic decision-making (13:19)
  • Dosing and administration of the recently FDA-approved first-line regimen of venetoclax and obinutuzumab; mitigation of risk for tumor lysis syndrome (16:03)
  • Mechanism of action of venetoclax; role of renal function in the decision to administer this agent (17:02)
  • Emerging data with the combination of ibrutinib or venetoclax with anti-CD20 antibodies (20:05)
  • Del(17p) and/or p53 mutation status and the selection of therapy for patients with CLL (22:09)
  • Role of bendamustine/rituximab in the management of CLL (26:43)
  • Perspective on the efficacy of venetoclax/obinutuzumab versus ibrutinib as first-line therapy for patients with CLL (28:38)
  • Case: A man in his mid-60s with del(17p) CLL and no IGHV mutation experiences a dramatic response to first-line ibrutinib (30:42)
  • Prolonged lymphocytosis during ibrutinib therapy (33:20)
  • Clonal evolution in CLL; importance of monitoring for del(17p) and p53 mutations before treatment initiation (35:35)
  • Sequencing of ibrutinib and venetoclax for patients with CLL; tolerability and quality of life with ibrutinib versus venetoclax (36:59)
  • Management of arthralgias associated with Bruton tyrosine kinase (BTK) inhibitors (40:25)
  • Case: A woman in her mid-70s with del(13q) CLL and no IGHV mutation receives acalabrutinib after experiencing disease progression on multiple lines of therapy, including ibrutinib (42:15)
  • BTK inhibitor-associated headaches and atrial fibrillation (44:18)
  • Efficacy of ibrutinib versus acalabrutinib; ongoing Phase III ACE-CL-006 study comparing acalabrutinib to ibrutinib for previously treated, high-risk CLL (47:31)
  • Case: A man in his late 70s with del(11q) CLL and no IGHV mutation attains a complete response and MRD-negative status with venetoclax and obinutuzumab on the Phase III CLL14 trial (51:59)
  • Side effects of venetoclax/obinutuzumab (53:36)
  • Case: A man in his early 70s with hairy cell leukemia (HCL) and a BRAF mutation experiences disease progression after receiving vemurafenib as second-line therapy (57:25)
  • Activity and tolerability of the recently FDA-approved antibody-drug conjugate moxetumomab pasudotox-tdfk in patients with relapsed/refractory HCL (59:10)
  • Novel approaches under investigation for HCL (1:01:11)
  • Case: A woman in her late 50s develops Richter’s transformation (RT) from CLL to diffuse large B-cell lymphoma (DLBCL) after receiving ibrutinib as second-line therapy (1:03:52)
  • Pathogenesis and frequency of RT in patients with relapsed/refractory CLL (1:06:45)
  • Comparison of the biology of Richter’s transformed versus de novo DLBCL; novel therapies under investigation for RT (1:10:06)

CME information and select publications

146 episodes